REMS for new biologic; CMO pair seeks high-volume orders;

> The FDA has required a risk evaluation and mitigation strategy for Xiaflex, the recently approved biologic from Auxilium Pharmaceuticals. Item

> A collaboration between Albemarle Corp. and PharmaCore aims to handle projects that require high-volume capacity. Release

> East African nations are considering counterfeit-drug legislation that threatens generics--to India's dismay. Article

> Formatech is celebrating the issuance of U.S. patent 7,659,310, "Methods of Enhancing Solubility of Agents," which covers novel formulation methods for hydrophobic compounds. Release

> The $20-million Abacus Parenteral Drug facility in Mukono, Uganda, is up and running, yielding cheaper drugs and displacing imports from Europe and India. Article

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.